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Western societies are aging due to an increasing life span, decreased birth rates, and improving social and health conditions. On the other hand,
the prevalence of cardiovascular (CV) and cerebrovascular (CBV) diseases rises with age. Thus, in view of the ongoing aging pandemic, it is
appropriate to better understand the molecular pathways of aging as well as age-associated CV and CBV diseases. Oxidative stress contributes
to aging of organs and the whole body by an accumulation of reactive oxygen species promoting oxidative damage. Indeed, increased oxidative
stress produced in the mitochondria and cytosol of heart and brain is a common denominator to almost all CV and CBV diseases. The mito-
chondrial adaptor protein p66Shc and the family of deacetylase enzymes, the sirtuins, regulate the aging process, determine lifespan of many
species and are involved in CV diseases. GDF11, a member of TGFb superfamily with homology to myostatin also retards the aging process via
yet unknown mechanisms. Recent evidence points towards a promising role of this novel ‘rejuvenation’ factor in reducing age-related heart
disease. Finally, telomere length is also involved in aging and the development of age-related CV dysfunction. This review focuses on the latest
scientific advances in understanding age-related changes of the CV and CBV system, as well as delineating potential novel therapeutic targets
derived from aging research for CV and CBV diseases.
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Introduction
Aging is a major risk factor for the occurrence of acute and chronic
cerebrovascular (CBV) and cardiovascular (CV) diseases, such as
stroke and myocardial infarction. Indeed, in currently used risk
scores such as the one of the European Society of Cardiology,1 the
weight of age surpasses that of any known CV risk factor. Of
note, visible age-related signs such as male pattern boldness, grey
hair, facial wrinkles as well as the presence of arcus corneae alone
or in combination with appearance factors such as earlobe crease
and xanthelsma provide additional risk prediction beyond known
CV risk factors.2
According to the World Health Organization, the European
population is projected to increase only slightly by 2020, from 894
to 910 million, but then to return to current levels by 2050.3 As a
consequence, the number of elderly people is expected to rise sub-
stantially. Indeed, the number of individuals aged 85 years and older
is projected to increase from 14 to 19 million by 2020 and to 40
million by 2050.3 The underlying process of global population aging
has been named ‘demographic transition’ in which both mortality
and fertility decline. Decreasing fertility together with improving
social and health conditions determine a further increase in lifespan
and play a key role in the aging pandemic that characterizes the 21st
century.4
Cardiovascular and CBV diseases are age-related pathologies.
Of three adults, at least one suffers from CV or CBV disease and
more than half of those are estimated to be over 60 years of age.
Of note, the average annual rate of a first CV or CBV event rises
from 3 per 1000 for men at 35–44 years of age to 74 per 1000
for those at 85–94 years of age. For women, comparable rates
occur 10 years later in life.5 –7
According to the latest data, only 30% of deaths in people aged
under 65 are caused by CV and CBV diseases, as are 37% of deaths
occurring before age 35; this means that more than half of deaths
related to CV and CBV diseases develops in individuals aged
65–74 years.8
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These alarming data urge for research focussing on the intercon-
nections between aging, CV, and CBV diseases in order to discover
novel therapeutic targets allowing to address the constantly increas-
ing clinical needs in elderly patients.
Theories of aging
Free radical theory of aging
One of the most accepted theories of the mechanism of aging is the
free radicals theory first conceived by Harman.9 It relies on the con-
cept that reactive oxygen species (ROS) produced during normal
aerobic metabolism tend to accumulate with age ultimately resulting
in oxidative damage of genomic DNA, proteins, and cellular compo-
nents.9 According to this theory, an increase in pro-oxidants would
promote, whereas an improvement in antioxidant defences would
delay the aging process.9 The relevance of this hypothesis has
been verified in vitro and in animal models by modulating genes dir-
ectly involved in the metabolism of ROS, such as superoxide (O2−)
dismutase that converts O2
− to hydrogen peroxide and then to
water; catalase that converts hydrogen peroxide to water and oxy-
gen; glutathione peroxidase that reduces lipid hydrogen peroxides
to their corresponding alcohols and free hydrogen peroxide to
water; thioredoxins that facilitate reduction of other proteins via
their dithiol-disulphide active site and detoxify peroxides; peroxire-
doxins that reduce hydrogen peroxides and peroxynitrite; and
methionine sulfoxide reductases that carry out the enzymatic
reduction of methionine sulfoxide to methionine.10– 14
Of note, reduced levels of these protective proteins are asso-
ciated with increased morbidity and reduced lifespan.10–14 In condi-
tions of elevated oxidative stress, O2− binds nitric oxide (NO)
resulting in the generation of peroxynitrite (ONOO2), another
highly reactive and toxic species which penetrates across the
phospholipid membrane causing substrate nitration damaging
DNA,15 oxidation of lipoproteins,16 disruption of mitochondrial
activities,17 nitrosylation of proteins, and further depletion of plasma
antioxidants.18
Nitric oxide is the most important regulator of the CV system.19
When the release of NO or its bioavailability is reduced,
endothelium-derived contracting factors become predominant, de-
termining the onset of endothelial dysfunction,20 the common de-
nominator of hypertension, diabetes, and hypercholesterolemia.21
Reduced NO bioavailability endorses adhesion of platelets and
leukocytes, as well as migration and proliferation of smooth muscle
cells which determine the first stages of atherosclerosis.20 The acti-
vation of other factors induced by ROS, such as the transcription
factor NF-kB, further promotes atherogenesis by the release of
several cytokines, such as tumour necrosis factor-a (TNF-a),
interleukin 6, monocyte chemoattractant protein-1, and adhesion
molecules, which collectively contribute to chronic inflammation,
a main determinant of atherosclerosis.22
The renin–angiotensin–aldosterone system (RAAS) is implicated
in aging by increasing tissue and mitochondrial oxidative stress.23
Angiotensin II (Ang II), the key effector molecule of RAAS, activates
via its receptor type 1 NADPH oxidase, which in turn generates
superoxide anion (O2
−). O2− promotes then uncoupling of endo-
thelial NO synthase, followed by impairment in NO bioavailability
and finally leads to enhanced ROS production. Activation of Ang
II and its consequent effects on free radical production are tightly
controlled under physiological conditions. Therefore, uncontrolled
Ang II-mediated ROS generation takes place as a result of age-
dependent RAAS activation.24 In addition, Ang II also accelerates
cellular senescence by telomere shortening.25
Telomere shortening theory of aging
Telomeres are a region of repetitive nucleotide sequences
(TTAGGG) found at the ends of chromosomes. They are consid-
ered to have several functions, including protection against degener-
ation, reconstruction, fusion and loss, as well as contributing to
pairing of homologous chromosomes. Telomeres are shortened
by 33–120 base pairs with each cell division, up to a critical length
which induces the loss of the complex nucleoprotein structure,
thereby triggering replicative senescence—a permanent non-
dividing state which ensues in somatic cells after a predetermined
number of cell divisions.26 Telomerase is an enzyme responsible
for maintaining the length of telomeres and it is highly expressed
in over 90% of cancers. It is believed that its upregulation is a crucial
mechanism for the avoidance of cellular senescence. Telomerase-
deficient mice are susceptible to progressive tissue atrophy, stem
cell depletion, organ system failure, and impaired tissue injury re-
sponses, which are reversed by telomerase reactivation.27 This sug-
gests that telomere shortening is the main determinant of cellular
aging. In addition, some associations between shorter telomeres
and CV diseases such as calcific aortic valve stenosis, atheroscler-
osis, and myocardial infarction have been shown over last dec-
ade.28 – 30 However, some concerns about this theory need to be
acknowledged. First of all, although telomere shortening may play
a role in determining lifespan in cells that continue to divide, it seems
unlikely to contribute to the aging process that occurs in postmitotic
cells. Additionally, the aging process is not limited to dividing cells. In
fact, several human cells, such as muscle cells (i.e. the heart among
other organs) or central nervous system neurons, do not divide dur-
ing adulthood, yet show progressive morphological signs of aging
during senescence. Of note, the correlation between telomere
length and age-related disorders is still a matter of debate.31 Where-
as some prospective studies showed association between short tel-
omeres and overall mortality,32 – 34 other studies did not find the
same association.35 – 37 The role of telomere shortening in cancer,
which can also be considered an age-related disease since its prob-
ability increases with age, is still not clear. Although numerous stud-
ies investigated the link between telomere length in malignant cells
and cancer progression or survival, this relationship still remains in-
sufficiently understood and requires further clarification.38,39
Therefore, despite existing evidence associating telomere length
and age-related diseases, neither conclusive causative link nor a pre-
dictable correlation can be postulated.
Genes regulating aging and
longevity
The histone deacetylases sirtuins
Sirtuins belong to class III histone deacetylases and have
mono-ADP-ribosyltransferase, lysine deacetylase, desuccinylase,
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depalmitoylase, demalonylase, and demyristoylase activity. Their
nicotinamide adenine dinucleotide (NAD+)-dependent enzymatic
activity has been associated to aging and it could represent an inter-
esting mediator of aging and age-associated CV/CBV diseases.40–42
Seven sirtuins which have different cellular localizations have
been reported in mammalians: Sirt1, that is localized in the nucleus
and in the cytoplasm, is implicated in the control of cell survival and
metabolism; Sirt2, localized in the cytoplasm, regulates cytoskeletal
reorganization, autophagy and metabolism; Sirt3, Sirt4 and Sirt5 are
located in the mithocondrium and regulate ROS production, apop-
tosis, and metabolism; Sirt6, localized in the nucleus, regulates gene
expression, cellular metabolism, and inflammatory response; Sirt7,
that is also in the nucleus, is implicated in gene transcription.43
Several members of sirtuin family have been demonstrated to
play a key role in human aging. Sirt1 endogenous expression has
been studied in young and old human donors of vascular smooth
muscle cells (VSMCs) (from 12- to 88-year-old subjects), demon-
strating an inverse correlation between the endogenous Sirt1 pro-
tein expression and the donor age.44 In particular, a trend toward
reduced mortality has been shown for Sirt1 haplotype 2 and
rs3758391 single-nucleotide polymorphism (SNP) carriers among
the 1245 participants of the Leiden 85-plus study,45 while a signifi-
cant 31% risk reduction was observed for the rs12778366 SNP car-
riers among the 1390 subjects of the Vlagtwedde/Vlaardingen
cohort.46 Several reports speculate also on the involvement of
Sirt3 in determining lifespan. Despite no significant difference in
Sirt3 mRNA or total Sirt3 protein expression of myocardial tissues
was observed between young and old patient groups, protein ex-
pression of the short isoform of Sirt3 (sh-Sirt3) was significantly in-
creased in young tissue vs. old tissue, whereas the expression of the
full-length Sirt3 (fl-Sirt3) was higher in the aged vs. the young
group.47 Several studies suggest that Sirt3 genetic variability might
be relevant for the modulation of human longevity. In particular a
silent G/T transversion at position 477 of the coding region
(G477T corresponding to Ser159Ser; AF083108) of Sirt3 gene
was observed in an Italian cohort from Calabria (801 subjects free
of clinically overt pathologies, 120 older than 100 years), with an im-
proved survival in males with TT genotype and a higher mortality in
males with GT genotype.48 Similarly, Sirt3 rs11555236 and
rs4980329 SNP carriers have been shown to be associated with
an improved survival in females in another Italian cohort from Tre-
viso.49 A recent study focused on the role of Sirt3, Sirt5, and Sirt6 on
human aging.50 It demonstrated in 3763 subjects that homozygous
minor allele genotypes within rs2841505 (Sirt5) and rs107251
(Sirt6) are associated with reduced survival, whereas homozygous
minor allele genotypes within rs511744 (Sirt3) determined an in-
creased lifespan.
The role of sirtuins in age-related CV/BCV diseases has been
deeply investigated. Sirt1 is considered an interesting target to delay
vascular aging through its antioxidant properties. In fact, it increases
the activity of catalase and induces manganese superoxide dismu-
tase, two key enzymes involved in controlling cellular ROS levels,
by deacetylation of the mammalian forkhead transcription factors
of the O class in response to oxidative stress.51
Additionally, Sirt1 expression and activity gradually decrease with
aging and in parallel to this, oxidative stress, which is a major cause of
atherosclerosis, increases.52,53 The protective role of Sirt1 in
atherosclerosis has been demonstrated in Sirt1-Tg/ApoE2/2 mice
which have shown reduced atherosclerotic plaque formation
when compared with ApoE2/2 following 10 weeks of high-fat diet.
Furthermore, in similar experiments mice overexpressing endothe-
lial cell-specific Sirt1 have maintained acetylcholine-induced relaxa-
tions of the aorta accompanied by upregulated endothelial NO
synthase (eNOS) thus confirming that Sirt1 modulates eNOS ex-
pression and activity.54 On the other hand, Sirt12/2/ApoE2/2
mice exhibit enhanced plaque formation.55 This suggests that during
high-cholesterol diet, Sirt1 suppresses atherogenesis by maintaining
endothelial cell survival and function. In a recent study, ApoE2/2
mice fed for 12 weeks with a high-cholesterol diet supplemented
with SRT3025, a pharmacological Sirt1 activator, showed reduced
plasma levels of LDL and total cholesterol as well as reduced plaque
formation. Considering that SRT3025 reduced the hepatic release
of acetylated PCSK9 and in turn increased the expression of
LDL-receptors and reduced plasma levels of LDL in ApoE2/2, but
not LDL-R2/2 mice reduction in PCSK9 appears the most likely
mechanism by which Sirt1 blunts atherosclerosis.56
Low levels of Sirt1 have been reported also in circulating periph-
eral blood mononuclear cells of patients with metabolic syn-
drome.57 In mice, Sirt1 overexpression is associated with reduced
levels of serum insulin and cholesterol together with a reduction
in adipose tissue volume and a decreased obesity-induced insulin re-
sistance.58,59 Additionally, Sirt1 could also play a role in the regula-
tion of whole-body metabolic homeostasis.60 Other members of
the Sirtuin family also affect glucose metabolism. In particular,
Sirt3 increases insulin sensitivity and decreases serum glucose,61
while Sirt4 inhibits glutamate dehydrogenase, which converts gluta-
mate to a-ketoglutarate in the mitochondrion, repressing amino
acid induced insulin secretion.62
Sirt1 together with Sirt3 and Sirt6 modulate cardiac hypertrophy
by regulating AKT, a gene that plays a central role in regulating a
variety of cellular processes ranging from cell survival to aging.63
Indeed, left ventricular hypertrophy represents a predictor of
outcome, since it lowers coronary reserve and enhances cardiac
oxygen requirements.
Furthermore, it appears that sirtuins are also involved in coronary
artery disease (CAD). Indeed, levels of Sirt1 mRNA have been eval-
uated in peripheral monocytes of 48 male subjects admitted for car-
diac catheterization and subdivided into individuals with normal
coronary arteries, patients with stable CAD and those with acute
coronary syndromes (ACS). Of note, Sirt1 levels were reduced
in patients with stable CAD and in those with ACS when compared
with those without angiographically demonstrable CAD. Interest-
ingly, Sirt1 levels correlated positively with HDL levels in all groups.
In line with this observation, THP-1 monocytic cells incubated with
HDL isolated from healthy subjects displayed increased Sirt1 pro-
tein expression when compared with cells incubated with HDL
from the CAD or ACS patients. Furthermore, PON1 activity, an im-
portant antioxidant enzyme assuring proper biological activity of
HDL,64 was reduced in HDL from patients with CAD or ACS,
indicating that PON1 activity is required to allow HDL to stimulate
Sirt1 expression.65
Taken together, sirtuins are potentially interesting therapeutical
targets for the treatment of age-related CV disease. In particular,
Sirt1 affects oxidative stress, metabolic syndrome, diabetes mellitus,
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cardiac hypertrophy, and atherosclerosis. The development of
molecules stimulating Sirt1 expression and activity supports this
concept. To date several natural and synthetic Sirt1-activating com-
pounds have been described.66,67 Natural plant-derived metabolites
able to activate Sirt1 in vitro include flavones, chalcones, anthocyani-
dins, and resveratrol that has been demonstrated to be the most
promising for therapeutical purposes.66 The first synthetic
Sirt1-activating compounds to be produced were chemically differ-
ent from resveratrol and presented an imidazothiazole scaffold
(SRT1460, SRT1720);68 recently, a more potent second generation
of synthetic Sirt1-activating compounds based on benzimidazole
and urea-based scaffold has been synthesized.69,70 However, even
if synthetic Sirt1-activating compounds seem to be promising in
in vitro studies, their clinical efficacy still requires to be tested. The
potential therapeutical role of the other members of the sirtuin
family still requires to be investigated.
In summary, by participating in transcriptional as well as in meta-
bolic cellular control sirtuins play a crucial role in adaptation to oxi-
dative, genotoxic, and metabolic stress processes all of which
increase with aging. In line with this concept, sirtuins should be con-
sidered as aging sensors, counteracting deleterious consequences of
biological events triggered by aging. Among sirtuins localized in the
nucleus, Sirt1 and Sirt6 both play an important role in preserving
vascular health and delaying onset of CV disorders, while the role
of Sirt7 is still unclear. The mitochondrial sirtuin Sirt3 is involved
in mitochondrial homeostasis, playing a protective role in the
heart.71
Adaptor protein p66Shc
The mitochondrial adaptor protein p66Shc is a key determinant of
aging; indeed, its genetic deletion in the mouse lowers levels of
ROS and prolongs lifespan by 30%.72 The mammalian SHC locus
encodes for three different isoforms with respective molecular
weights of 46, 52, and 66 kDa. Due to its unique NH2-terminal re-
gion, p66Shc is the only protein that plays a role in redox metabol-
ism.72 P66Shc regulates ROS production by controlling the partition
of ATP generation in the cell and by participating to the electron
flow chain in the mitochondria, a major source of cellular ROS,
by opening the mitochondrial permeability transition pore (PTP)
(Figure 1).73 In p66Shc2/2 mice, levels of intracellular ROS are
reduced as is oxidative damage of DNA and proteins. Furthermore,
their cells are more resistant to paraquat-induced oxidative
stress.72,74
The pivotal role of p66Shc in oxidative stress, together with the
fact that p66Shc levels increase with aging, makes this adaptor pro-
tein a plausible target for age-dependent CV and CBV diseases.
The potential role of p66Shc is particularly promising in stroke. First,
age-dependent endothelial dysfunction of the basilar artery is
blunted in aged p66Shc2/2 mice when compared with age-matched
wild type due to reduced ROS production in the former compared
with the latter.75 Secondly, p66Shc is crucially involved in endothelial
dysfunction induced by hypertension, a major risk factor for stroke.
Indeed, exposure of human aortic endothelial cells to cyclic stretch
leads via integrin a5b1 and the c-Jun N-terminal kinase to a stretch-
and time-dependent phosphorylation of p66Shc at Ser36. In parallel,
nicotinamide adenine dinucleotide phosphate oxidase (NADPH
oxidase) is activated and the production of ROS increases,
meanwhile NO bioavailability decreases. In this setting, silencing
of p66Shc blunts stretch-increased O2
− production and activation
of NADPH oxidase, thus restoring NO bioavailability through a re-
duced scavenging action of O2
−. In line with the above, activation of
p66Shc is increased in isolated aortic endothelial cells of spontan-
eously hypertensive compared with normotensive Wistar Kyoto
rats.76 Finally, p66Shc knockout mice display decreased production
of free radicals in the brain and systemically and have smaller strokes
in an ischaemia-reperfusion injury model using middle cerebral
artery occlusion. In line with smaller strokes, p66Shc2/2 mice also
exhibit preserved neurological function.77 Similarly, post-ischaemic
in vivo silencing of p66Shc upon reperfusion improves stroke out-
come in wild-type mice while its expression correlates well with
short-term outcome in patients with ischaemic stroke (Figure 2).78
A major mechanism for the reduced stroke size and neurological
deficits in p66Shc2/2 mice and in those in which p66Shc was silenced
at the time of ischaemia and reperfusion with specific siRNA,
appears to be the regulation of proteins such as claudin-5 involved
in the permeability of the blood–brain barrier. Indeed, in mice sub-
jected to ischaemia and reperfusion of the middle cerebral artery,
p66Shc increases in brain oedema and thereby contribute to
anexpanding stroke with greater neurological deficits over time
and lower survival. Of great clinical importance is the fact that in
patients with acute stroke, the expression of p66Shc is increased
and that this increase is related to their neurological deficit as
assessed by the NIH Stroke Score.
P66Shc is also involved in the effects of risk factors particularly
important in atherosclerosis. Indeed, incubation of human aortic
endothelial cells with oxidized low-density lipoprotein (oxLDL)
leads to phosphorylation of p66Shc at Ser36 that is prevented by
inhibition of the lectin-like oxLDL receptor-1 (LOX-1). Silencing
of p66Shc blunts oxLDL-induced ROS production, underscoring
the critical role of p66Shc in oxLDL-induced oxidative stress in endo-
thelial cells.79,80 In line with these in vitro findings, p66Shc2/2/
ApoE2/2 mice subjected to a high-cholesterol diet exhibit markedly
reduced plaque formation suggesting that the adaptor protein
facilitates the atherosclerotic process.
Furthermore, p66Shc is involved in the vascular and myocardial
changes occurring in diabetes mellitus.81,82 Indeed, in streptozotocin-
induced diabetes of the mouse, endothelium dysfunction is markedly
attenuated in p66Shc2/2 mice when compared with their wild-type
littermates. Importantly, monocytes obtained from patients with
diabetes exhibit enhanced expression of the adaptor protein. Finally,
mice with streptozotocin-induced diabetes develop diabetic cardio-
myopathy with impaired left ventricular function, a process that is
abrogated in p66Shc2/2 mice by improved function of resident
stem cells.
So far most interventions aiming at reducing CV events in
diabetics have failed. Therefore, the concept of hyperglycaemic
memory has evolved providing an explanation why hyperglycaemia
promotes vascular dysfunction even after glucose normalization.
Interestingly, in human aortic endothelial cells exposed to high
glucose and aortas of diabetic mice, activation of p66Shc by protein
kinase C bII persists even after re-establishment of normoglycaemia,
with continued production of ROS, reduced NO bioavailability, and
apoptosis. On the other hand, in vitro and in vivo gene silencing of
p66Shc, performed at the time of glucose normalization, suppresses
Molecular mechanism of vascular aging 3395
ROS production, restores endothelium-dependent relaxation, and
attenuates apoptosis.83
Recently, it has been proposed that prolyl isomerase Pin1 plays an
important role in the regulation of aging and participates in the mito-
chondrial translocation of p66Shc.84 Of note, Pin1 inhibition pre-
vents oxidative stress and mitochondrial disruption in cultured
human endothelial cells and also in mice under hyperglycaemic
conditions.85
As p66Shc is involved in the effects of most of CV risk factor on the
endothelium, it would be expected to play a key role in myocardial
infarction as well. Indeed, in peripheral blood monocytes of patients
with ACS, RNA levels of p66Shc are increased when compared with
patients with CAD or normal coronary arteries. Furthermore,
p66Shc expression is directly related to malondialdehyde levels, a
marker of lipid peroxidation and systemic oxidative stress.86 How-
ever, in contrast to these preliminary clinical findings, genetic dele-
tion or in vivo silencing of p66Shc is associated with larger infarcts
after 30 min of occlusion of the left anterior descending artery
followed by 24 h of reperfusion (Figure 3).87 Of note, this effect
was not seen when coronary occlusion time was prolonged to 45
or 60 min. These findings are in contrast with previous findings
where perfused murine hearts devoid of p66Shc subjected to
40 min of global ischaemia followed by 15 min of reperfusion
were significantly protected from ischaemia-reperfusion damage.88
In light of the above, it is still unclear whether the discrepancies ob-
served are due to in vivo vs. in vitro preparation or due to the differ-
ence in the severity of the insult. Possibly, p66Shc plays a different role
in the blood vessel wall, in endothelial cells and monocytes than in the
myocardium where it appears to play a protective role against ischae-
mia. Indeed, the damaging effects of p66Shc in stroke are entirely re-
lated to its effects on endothelial cells since neurons do not express
the adaptor protein.
The adaptor protein p66Shc has been considered to act as an aging
gene based on a study using a limited number of mice.72 However, a
recent study employing a much larger cohort of mice showed no in-
crease in life span in mice with genetic deletion of p66Shc pointing
Figure 1 Core signalling in JunD-, GDF11-, Sirt1-, and p66Shc-mediated pathways. JunD pathway: complex formation of the phosphorylated
JunD with the member of the Fos family causes formation and nuclear accumulation of the AP-1 transcription complex which directly regulates
gene transcription in association with other cofactors. GDF11 pathway: GDF11-mediated complex formation of the phosphorylated SMAD2/3
with SMAD4 causes nuclear translocation and accumulation of active contraction of Sma and Mad complexes, which directly regulate gene tran-
scription together with other cofactors. SIRT1 pathway: cytoplasmic Sirt1 directly deacetylates different target proteins using nicotinamide aden-
ine dinucleotide as a cofactor, whereas nuclear Sirt1 directly deacetylates key histone residues within DNA-nucleosome complex and thus leads
to inactivation of gene transcription. P66Shc pathway: complex formation with transporter inner membrane-transporter outer membrane import
system causes mitochondria translocation and accumulation of active adaptor protein p66Shc, which directly regulate opening of PTP in conjunc-
tion with phosphorylated transcription factor Stat3. JNK, c-Jun N-terminal kinases; ERK, extracellular signal-regulated kinases; GDF11, growth
differentiation factor 11; ALK, activin receptor-like kinase; ACTR, activin receptors; SMAD, contraction of Sma and Mad (Mothers against dec-
apentaplegic); Sirt1, silent-mating type information regulation 2 homolog 1; NAD+, nicotinamide adenine dinucleotide; TIM, transporter inner
membrane; TOM, transporter outer membrane; Stat3, signal transducer and activator of transcription 3; PTP, permeability transition pore.
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out that perhaps the role of p66Shc in determining lifespan is not yet
clear.89 Additionally, the same study also demonstrated the role of
p66Shc on several disease processes including insulin signalling, stress
resistance, and energy metabolism. Therefore, additional research is
required in order to fully understand the extent of p66Shc influence
on lifespan and age-related changes under physiological and patho-
physiological conditions.
Nonetheless, the above-described data address the aging gene
p66Shc as a valuable therapeutic target in endothelial dysfunction
and vascular disease, whereas its role in myocardial infarction still re-
quires further investigation.
The transcription factor JunD
JunD is the last discovery in Jun family of activator protein-1 tran-
scription factor complex. In contrast with two other members of
Jun family, c-jun and JunB, JunD shows different gene regulation
profile and function (Figure 1).90 Interestingly, mice with genetic de-
letion of JunD are viable, whereas the deletion of either c-jun or
JunB is embryonically lethal.91 JunD can act as positive or negative
regulator of transcription of a broad variety of cell-type-specific
genes involved in oxidative stress, cell proliferation, and differenti-
ation.92 – 94 Experimental data over the last decade have shown
the protective role of JunD against oxidative stress by modulating
the expression of several free radical scavenging enzymes.95 In add-
ition, recent evidence was obtained pointing out that JunD may
protect from aging-induced endothelial dysfunction and thus may
be considered as a novel target to prevent ROS-mediated vascular
aging (Figure 4).96 Both young and old JunD knockout mice showed
impaired endothelium-dependent relaxation when compared with
age-matched wild-type control mice. Endothelial dysfunction was
associated with age-independent decrease in endothelial NO re-
lease, eNOS activity, and increase in mitochondrial O2
− generation
and ONOO2 levels. In contrast, JunD in vivo overexpression re-
stored endothelial function.96 Of note, JunD expression was signifi-
cantly reduced in peripheral blood monocytes of old healthy
subjects and was correlated with the expression of scavenging and
oxidative enzymes.96 Finally, JunD expression was decreased in
heart failure patients suggesting that it may be protective from
aging-related cardiac dysfunction.97,98
Growth differentiation factor 11
Growth differentiation factor 11 is a member of TGFb superfamily
with homology to myostatin (Figure 1). Interestingly, in mice its levels
decline with age, whereas myostatin and TGFb1 levels remain un-
changed, suggesting a role of this molecule in aging process.99 Of
note, GDF11 is involved in cardiac hypertrophy. In line with this, old
mice exposed for 4 weeks to the blood circulation of young mice
by heterochronic parabiosis—a surgical model by which the circula-
tory system of two mice, a young one and an old one, are joined to-
gether so as to have a single circulatory system—cardiac hypertrophy
Figure 2 Impact of p66Shc on stroke. (A) Diffusion-weighted imaging denotes reduced lesions in stoke mice silenced in vivo post-ischaemicaly
with sip66Shc (diffusion-weighted imaging: n ¼ 5) compared with siScr stroke mice (n ¼ 7) at 48 h post-middle cerebral artery occlusion. Right
panel: representative MRI images. Data are expressed as mean+ SEM; ** P, 0.01 for sip66Shc stroke vs. siScr stroke. (B) P66Shc gene expression
in peripheral blood monocytes from ischaemic stroke patients. Real-time PCR determined increased p66Shc mRNA levels in stroke patients 6 h
(n ¼ 27), but not 24 h (n ¼ 16) after initial stroke symptoms compared with the levels of control subjects (n ¼ 19). Data are expressed as mean+
SEM; ***P, 0.001 (adapted from Spescha et al.78).
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dramatically regressed, along with a reduced cardiomyocyte size and
molecular remodelling. Growth differentiation factor 11 is a determin-
ant of this phenomenon, since treating old mice with GDF11 to reach
youthful levels reproduced the effects of parabiosis and also reversed
age-related cardiac hypertrophy.100
Furthermore, GDF11 also shows therapeutic potential in
age-related neurodegenerative and neurovascular diseases. In fact,
after 5 weeks of exposure to the circulation of young mice by het-
erochronic parabiosis old mice exhibited active cerebral vascular re-
modelling, culminating in increased neurogenesis. These effects
were reproduced by treating old mice with daily injections of
GDF11 in order to reach the circulating concentrations of GDF11
of young mice.101 Although the current evidences on GDF11 are
still limited, the above-reported data indicate a potential key role
of GDF11 in reversing several pathological processes associated
with aging and, consequently, with age-related CV and CBV
diseases.
Clinical perspectives
Life style and caloric restriction
The relationship between lifestyle, dietary factors, and CV/CBV dis-
eases has been a focus of scientific research for almost half century.
Interestingly, physical training, a life style measure known to reduce
CV risk, increases the activity of Sirt1 by enhancing nicotinamide
phosporibosyltransferase and thereby the production of sirtuin-
fuelling NAD+. Additionally, exercise training normalizes the
age-associated shift in redox balance, since trained animals have
lower levels of carbonylated proteins, reduced expression of hy-
poxiainducible factor-1a and of vascular endothelial growth factor.
Furthermore, also the age-associated increase in the level of Sirt6 is
attenuated by exercise training. While data on other aging and lon-
gevity pathways are still missing, it appears that regular exercise de-
celerates the effects of the aging process via sirtuin-dependent
pathways.102
Resveratrol (3,4′,5-trihydroxystilbene), a small polyphenol found
in various berries, nuts, grapes, wine, and other plants sources,
might be more promising for its anti-inflammatory, antioxidant,
and anti-aging effects.103 It is a natural activator of Sirt1 and binds
the Sirt1 enzyme-peptide substrate complex at an allosteric site
amino-terminal to the catalytic domain thus lowering the Michaelis
constant for acetylated substrates.68 In line with this and as Sirt1 is
involved in the regulation of glucose metabolism, in diet-induced ob-
ese and genetically obese mice, resveratrol improves insulin sensitiv-
ity, lowers plasma glucose, and increases mitochondrial capacity.58
Additionally, in rats, resveratrol improves whole-body glucose
homeostasis and insulin sensitivity in adipose tissue, skeletal muscle,
and liver.68 However, these promising findings obtained in preclin-
ical studies were not completely confirmed at the clinical level where
results have been contrasting.104,105 In particular, 8-week administra-
tion of resveratrol did not reduce insulin sensitivity, liver steatosis,
or abdominal fat distribution in overweight or obese individuals with
clinically established non-alcoholic fatty disease105 Similarly, the bene-
fits induced by resveratrol in reducing atherosclerosis progression in
ApoE2/2 mice were not completely confirmed in patients.106,107
Caloric restriction (CR) is a dietary regimen that improves health
and slows aging by limiting dietary energy intake. In different species
from yeast to mammals, CR delays the onset of age-associated dis-
eases, including cancer, atherosclerosis, and diabetes.108 Decreased
systemic oxidative damage has been proposed as a mechanism and
increasing evidence suggests that Sirt1 could play a key role in me-
diating the benefits induced by CR.109 In mice maintained for 3
months on CR, the amount of mitochondrial DNA, expression of
peroxisome proliferator-activated receptor-Y coactivator 1a
(PGC-1a), nuclear respiratory factor-1, mitochondrial transcription
factor A (Tfam), expression of cytochrome c oxidase (COX-IV), and
cytochrome c (Cyt c), that are two mitochondrial proteins involved
Figure 3 Genetic deletion of p66Shc leads to larger infarcts.
(A) Quantification of infarct size (I) per V with the representative
images of 2-3-5-triphenyl tetrazolium chloride-stained middle
heart sections of control wild-type and p662/2 mice after
30 min of ischaemia followed by 24 h of reperfusion. n ¼ 11 for
wild type and n ¼ 14 for p662/2 (B) Serum cardiac troponin I
(cTnI) levels of WT or p662/2 after ischaemia and reperfusion in-
jury. n ¼ 10 for both genotypes. Data are mean+ SEM; *P, 0.05
vs. wild type (adapted from Akhmedov et al.87).
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in cell respiration, oxygen consumption, and expression of mitofusin
1 and 2 was higher in white adipose tissue and other tissues com-
pared with mice fed a normal diet, suggesting a role of CR in improv-
ing mitochondrial function. These processes were paralleled by an
increased eNOS and Sirt1 expression that could explain the benefits
induced by CR on lifespan and age-related CV and CBV diseases.108
In monkeys assigned to CR, individually determined baseline in-
take was reduced by 10% per month over a 3-month period to
reach the desired 30% restriction. Animals were fed a semi-purified,
nutritionally fortified, low-fat diet containing 15% protein and 10%
fat. Monkeys undergoing CR have shown an improved age-related
and all-cause mortality when compared with control animals.110
Additionally, CR was shown to have no impact on non-age-related
deaths.110
In mice assigned to CR, consisting in a 30% restriction of caloric
intake for 7 days, infarct size following permanent coronary ligation
was reduced when compared with mice assigned to an ad libitum
diet. Additionally, CR mice showed higher ejection fraction and
dP/dt max as well as smaller end-systolic volume when compared
with mice fed ad libitum at 2 days post-myocardial infarction. Caloric
restriction diet was associated with increased levels of phosphoryl-
ation of Akt and GSK3b, reduced levels of phosphorylated AMPK
and mitochondrial-related proteins PGC-1a, cytochrome c, and cy-
clooxygenase IV, with no differences in the levels of phosphorylated
eNOS or MAPK (ERK1/2; p38) and reduced protein abundance of
cleaved caspase3 in the infarcted heart.111
Caloric restriction was demonstrated to impact also cardiac re-
modelling. Indeed, in DS/obese rats (with metabolic syndrome
and hypertension), 35% CR for 4 weeks reduced body fat content,
ameliorated left ventricular hypertrophy, fibrosis, diastolic dysfunc-
tion, and attenuated cardiac oxidative stress and inflammation when
compared with rats fed ad libitum.112 Similarly, in mice assigned to
CR, consisting in a 40% restriction of caloric intake for 4 weeks,
morphological and functional changes (left ventricular hypertrophy,
impaired left ventricular relaxation) following ascending aortic
constriction were less evident when compared with mice fed
ad libitum.113
The impact of CR on the key features of arterial aging has also
been investigated. In mice, life-long 40% CR blunted the increase
in blood pressure, arterial stiffness, and carotid wall thickness in-
duced by aging when compared with mice fed ad libitum. Similarly,
CR attenuated nitrotyrosine and superoxide production blunted
the increase in NADPH activity and p67 expression resulting in an
increase of SOD and an enhanced NO bioavailability thus prevent-
ing age-induced endothelial dysfunction.114
The importance of specific diet regimens and CR in reducing CV
risk has been demonstrated also in humans. The INTERHEART
study confirmed the potential protective role of fruit and vegetable
consumption on the risk of developing myocardial infarction,115
whereas in the PREDIMED study Mediterranean diet supplemented
with extra-virgin oil or with mixed nuts reduced the risk of major
CV events by 30% when with a traditional low-fat diet,116 supporting
Figure 4 Role of JunD in vascular aging. (A and B) Representative western blot (A) and densitometric quantification (B) of JunD protein expres-
sion from aortic lysates of young and old wild-type mice. (C) Age-dependent changes in endothelium-dependent relaxation in aortic rings from
wild-type and JunD2/2 mice. Line graphs show concentration–response curves to acetylcholine. Results are presented as mean+ SEM; n ¼ 5–7
per group. NE, norepinephrine. *P, 0.05 (adapted from Paneni et al.96).
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the hypothesis that specific diet regimens can reduce CV risk. The
benefits induced by CR in humans have been also directly demon-
strated by an additional study whereby 18 subjects who had been on
CR for an average of 6 years were age-matched to 18 healthy indi-
viduals on typical American diets. Serum total cholesterol, LDL
cholesterol, ratio of total cholesterol to HDL cholesterol, triglycer-
ides, fasting glucose, fasting insulin, CRP, PDFG-AB, and systolic and
diastolic blood pressure were all markedly lower, whereas HDL-C
was higher, in the CR than in the American diet group. Additionally,
carotid artery IMT was 40% less in the CR group than in the com-
parison group.117 In the CALERIE trial, participants were rando-
mized to 1 of the following 4 groups for 6 months: control
(weight maintenance diet); CR (25% CR of baseline energy require-
ments); CR with exercise (12.5% CR plus 12.5% increase in energy
expenditure by structured exercise); very low-calorie diet (890 kcal/
day until 15% weight reduction, followed by a weight maintenance
diet). At 6 months, fasting insulin levels were significantly reduced
from baseline in the intervention groups, whereas DHEAS and glu-
cose levels were unchanged. Core body temperature was reduced
in the CR and CR with exercise groups. Sedentary 24-h energy ex-
penditure was decreased in the CR, CR with exercise, and very low-
calorie diet groups, but not in controls.118 Finally, in another study
enrolling 25 subjects practicing CR for 6.5+4.6 years and 25 age-
and gender-matched control subjects consuming Western diets,
standard transmitral Doppler flow diastolic function indexes of
the CR group were similar to those of younger individuals, and
model-based image processing, flow-derived diastolic function
indexes, reflecting chamber viscoelasticity and stiffness, were signifi-
cantly lower than in control subjects. Additionally, blood pressure,
serum C reactive protein, TNF-a, and TGF-b1 levels were signifi-
cantly lower in the CR group compared with the Western diet
group, demonstrating that CR has cardiac-specific effects that ameli-
orate aging-associated changes in diastolic function119 (refer to
Table 1 for a summary of all recent basic research and clinical
studies).
Arterial stiffness
Age is an important determinant of pulse wave velocity.120 The wall
of large arteries, in particular the aorta, becomes thicker and less
elastic with age, resulting in an increased pulse wave velocity, an
important parameter of arterial stiffness.140 In general, arterial
stiffness reflects gradual fragmentation and loss of elastin fibres with
simultaneous accumulation of stiffer collagen fibres in the media layer
of large arteries and normally occurs independently of any other
processes. Because arterial compliance is determined as a ratio of
collagen to elastin, aging is associated with a decrease of this ratio
due to accelerated degradation of elastin and accumulation of stiffer
collagen. Such elastin degradation is further associated with progres-
sion in aortic stiffness and mortality.121 Increased arterial stiffness
reduces the reservoir function of the affected arteries and increase
pulse wave velocity, thus increasing systolic and pulse pressure.
Arterial stiffening is considered to be a predictor of several CV
outcomes, such as stroke, myocardial infarction, and kidney
diseases.122–124 In a recently published Framingham Heart Study Off-
spring cohort, it has been shown that increased aortic stiffness was
associated with the higher risk of incident hypertension125 (refer to
Table 1 for a summary of all recent basic research and clinical studies).
Pharmacological interventions
Recently, several cohort studies or randomized controlled trials at-
tempted to assess the benefits provided by food additives assumed
to decrease oxidative stress in large populations. Vitamins, due to
their antioxidant properties in vitro, are of particular interest
in this context and, indeed, in a first study daily vitamin E intake
of .100 IU reduced atherosclerosis progression and event
rates.126,127 However, the hypothesis that vitamin E supplementa-
tion could reduce atherosclerosis progression and clinical events
was not confirmed by later studies. In the Vitamin E Atherosclerosis
Prevention Study,128 353 subjects older than 40 years, with high
LDL cholesterol levels and no clinical signs or symptoms for CV
disease were randomized to DL- a-tocopherol 400 IU per day, or
placebo and followed every 3 months for an average of 3 years.
Compared with placebo, a-tocopherol supplementation signifi-
cantly raised plasma vitamin E levels, reduced circulating oxidized
LDL and reduced LDL oxidative susceptibility, but did not influence
the progression of carotid intima-media thickness over a 3-year per-
iod. In another study, the Alpha-Tocopherol Beta-Carotene Cancer
Prevention Study,129 men with a previous myocardial infarction ran-
domized to alpha-tocopherol displayed a significant reduction in
non-fatal myocardial infarction, but at the same time, a more rele-
vant increase in fatal CAD risk; similarly subjects receiving the com-
bination of a-tocopherol and b-carotene exhibited an increase in
fatal CAD. In subjects without history of myocardial infarction en-
rolled in the same study s-tocopherol alone or in combination
with bb-carotene did not affect fatal CAD nor non-fatal myocardial
infarction risk. Possibly, vitamin E supplementation suppresses cellu-
lar antioxidant systems (as it was demonstrated for ubiquinol-10 )130
or does not reach high enough levels in cellular compartments to
exert its antioxidant effects. Furthermore, it is conceivable that vita-
min E may become pro-oxidant in the absence of sufficient levels of
other antioxidants. Finally, in the HOPE trial a combination of vita-
mins did not affect clinical outcome; indeed, in a subset it increased
the incidence of heart failure.131 Thus, reducing ROS levels using ex-
ogenous antioxidants such as vitamins does not induce any benefit
in terms of reduction of CV/CBV risk.
Angiotensin-converting enzyme (ACE) could represent an add-
itional interesting target for pharmacological intervention; indeed,
ACE converts biologically inactive angiotensin I (Ang I) into active
angiotensin II (Ang II), a potent vasoconstrictor, and its inhibitors
are already an established therapeutical principle for the treatment
of hypertension. Activation of vascular ACE may also influence
VSMC growth and oxidative state of the vessel wall.141 In addition,
production of ROS (superoxide and hydrogen peroxide) enhanced
by Ang II, has been associated with vascular inflammation, athero-
sclerosis, hypertrophy, remodelling and angiogenesis,132,142 all of
which represent important components of age-dependent vascular
dysfunction. Angiotensin-converting enzyme inhibitors block activa-
tion of renin–angiotensin system and slow down the progression of
heart failure and atherosclerosis.132,142 Several clinical trials with
ACE inhibitors also showed reduced overall mortality and pro-
longed life expectancy in patients suffering from myocardial infarc-
tion.133 – 138 Other large-scale trials, in particular CAPP with
captopril, HOPE with ramipril, SOLVD with enalapril and PEACE
with trandolapril, showed reduced incidence in de novo diabetes
connected to ACE-inhibitor therapy.138,139,143,144
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Table 1 Overview of recent clinical and basic research studies focusing on vascular aging
Study Findings
Koltai et al.102 Physical training in rats Increases Sirt1 activity by enhancing NAMPT and Sirt-fueling
NAD+
Normalizes the age-associated shift in redox balance
Attenuates the age-associated increase in the levels of Sirt6
Banks et al.58 Resveratrol in diet-induced obese and genetically
obese mice
Improves insulin sensitivity
Lowers plasma glucose
Increases mitochondrial capacity
Milne et al.68 Resveratrol in rats Improves whole-body glucose homeostasis
Improves insulin sensitivity in adipose tissue, skeletal muscle,
and liver
Me´ndez-del Villar et al.104 Resveratrol in patients with metabolic syndrome Decreases weight, BMI, waist circumference, and fat mass
Decreases insulin secretion
Chachay et al.105 Resveratrol in overweight or obese individuals
with clinically established non-alcoholic fatty
disease
Does not reduce insulin sensitivity
Does not reduce liver steatosis
Does not reduce abdominal fat distribution
Norata et al.106 Resveratrol in ApoE2/2 mice Reduces the presence of atherosclerotic plaque by 40 and 36%
in the aortic sinus and in the ascending aorta, respectively
Sahebkar et al.107 Resveratrol in humans Does not affect lipid plasma levels
Nisoli et al.109 Caloric restriction in males Induces endothelial nitric oxide synthase expression
Induces 3′ ,5′-cyclic guanosine monophosphate formation
Induces mitochondrial biogenesis
Induces oxygen consumption
Induces adenosine triphosphate productionInduces
expression of Sirt1
Colman et al.110 Caloric restriction in monkeys Improves age-related and all-cause mortality
Noyan et al.111 Caloric restriction in mice Reduces infarct size following permanent coronary ligation
Determinates higher ejection fraction when compared with
controls
Determinates higher dp/dt max values when compared with
controls
Determinates smaller end-systolic volume as compared with
controls
Takatsu et al.112 Caloric restriction in mice with metabolic
syndrome and hypertension
Reduces body fat content
Ameliorates left ventricular hypertrophy
Ameliorates fibrosis
Ameliorates diastolic dysfunction
Attenuates cardiac oxidative stress and inflammation
Kobara et al.113 Caloric restriction in mice Attenuates morphological and functional changes following
ascending aortic constriction
Donato et al.114 Caloric restriction in mice Blunts the increase in blood pressure induced by aging
Blunts the increase in arterial stiffness induced by aging
Blunts the increase in carotid wall thickness induced by aging
Attenuates oxidative stress
Enhances endothelial function
INTERHEART study115 Fruit/vegetable consumption in humans Reduces risk of myocardial infarction
PREDIMED study116 Mediterranean diet in humans Reduces the risk of major CV events
Fontana et al.117 Caloric restriction in humans Reduces serum total cholesterol, LDL cholesterol, ratio of
total cholesterol to HDL cholesterol, triglycerides
Reduces fasting glucose, fasting insulin
Reduces CRP
Reduces blood pressure
Increases HDL cholesterol
CALERIE study118 Caloric restriction in humans Reduces fasting insulin levels
Reduces core body temperature and sedentary 24h energy
expenditure
Meyer et al.119 Caloric restriction in humans Ameliorates aging-associated changes in diastolic function
AlGhatrif et al.120 Arterial Stiffness in humans Increases with age and is sex dependent
Smith et al.121 Arterial Stiffness in humans Associated with elastin degradation and overall mortality
Continued
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Simultaneous intervention on multiple targets using multiple
pharmacological agents holds several promises which deserve add-
itional investigation. Additionally, discovery of novel therapeutical
targets, such as ROS-producing enzymes, angiotensin receptor sub-
types, and specific metabolic pathways will likely represent major
areas of research in the years to come. Finally, the use of modern
molecular tools, such as antisense gene therapy or blocking
antibody will certainly be implemented (refer to Table 1 for a sum-
mary of all recent basic research and clinical studies).
Conclusions
Sirtuins, p66Shc, JunD, and GDF11 have all been demonstrated to
play a key role in aging and age-related CV and CBV diseases;
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Table 1 Continued
Study Findings
Karras et al.122 Arterial Stiffness in humans Associated with all-cause mortality and CV events in chronic
kidney disease
Hashimoto et al.123 Arterial Stiffness in humans Linked to an increased risk of stroke in hypertension
Kitzman et al.124 Arterial Stiffness in humans Contributes to exercise intolerance in heart failure patients
Kaess et al.125 Arterial Stiffness in humans Associated with higher risk of incident hypertension, but
not with initial blood pressure
Stempfer et al.126 Vitamin E supplements in middle-aged women Are associated with a reduced risk of coronary heart disease
Rimm et al.127 High consumption of vitamin E in men Is associated with a lower risk of coronary heart disease
VEAPS128 Vitamin E supplements in humans Reduces circulating oxidized LDL
Reduces LDL oxidative susceptibility
Does not reduce the progression of IMT
Alpha-Tocopherol Beta-Carotene
Cancer Prevention study129
Alpha-tocopherol or beta-carotene supplements
in humans
Do not reduce major CV events
Increase the risk of fatal coronary heart disease
HOPE trial (vitamin E
sub-analysis)130,131
Long-term vitamin E supplementation Does not prevent cancer
Does not prevent major CV events
May increase the risk of heart failure
SOLVD trial132 Enalapril in patients with asymptomatic left
ventricular dysfunction
Reduces the incidence of heart failure and the rate of related
hospitalizations
Reduces the incidence of diabetes, especially in presence of
impaired fasting plasma glucose
GISSI-3 trial133 6 months Lisinopril treatment in patients with
acute myocardial infarction within 24 h
of onset of symptoms
Reduces the risk of death or severe ventricular dysfunction
ISIS-4 trial134 1 month captopril therapy Reduces the risk of mortality
SAVE trial135 Captopril in patients after an acute myocardial
infarction and with left ventricular dysfunction
without overt heart failure
Reduces the risk of mortality
Reduces the risk of fatal and non-fatal CV events
Reduces the risk of developing severe heart failure
Reduces the risk of heart failure hospitalization
EUROPA trial136 Perindopril in patients with previous myocardial
infarction or coronary artery disease
Reduces the risk of CV death or myocardial infarction or
cardiac arrest
HOPE trial137 Ramipril in high risk patients without heart failure Reduces the risk of myocardial infarction or stroke or CV
death
Reduces the risk of CV death
Reduces the risk of myocardial infarction
Reduces the risk of stroke
Reduces the risk of all-cause death
Reduces the risk of revascularization procedures
Reduces the risk of cardiac arrest
Reduces the risk of heart failure
Reduces the risk of complications related to diabetes
CAPPP trial138 Captopril in patients with hypertension Reduces the risk of fatal and non-fatal myocardial infarction,
stroke, and other CV death
Reduces CV mortality
Reduces the risk of fatal and non-fatal myocardial infarction
Reduces the risk of new onset of diabetes mellitus
PEACE trial139 Trandolapril in patients with stable coronary
artery disease and normal or slightly reduced
left ventricular function
Reduces the risk of CV death or myocardial infarction or
coronary revascularization
Reduces the risk of diabetes
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thus, they could represent important therapeutical targets to face
the ongoing aging pandemic.
Sirtuins are involved in several processes, such as ROS production,
apoptosis, and metabolism. Resveratrol, a polyphenolic Sirt1-activating
compound found in grapes and wine has been demonstrated to exert
several beneficial effects on CV and CBV diseases in animal and in vitro
models but its effects in humans are still unclear. Physical exercise has
been shown to exert beneficial effects on aging and CV and CBV
diseases through Sirt1-dependent pathway.
JunD as a distinct member of the Jun family is implicated in aging.
Showing a unique regulation and expression profile, it can activate
or repress the transcription of a broad collection of target genes
involved in oxidative stress, cell growth, and differentiation. Recent
research has provided a number of evidences for a protective role of
JunD in aging-induced endothelial dysfunction thus representing a
selectable novel target to prevent age-related CV and CBV diseases.
P66Shc exerts its effects on aging and CV and CBV diseases pre-
venting ROS-mediated cell damage and, consequently, reducing cel-
lular apoptosis. Although, several clinical trials have shown that
reducing oxidative stress by antioxidant treatments is not the key
for treating age-related diseases, one hypothesis to explain these
findings is that the inhibition of ROS production (i.e. decreasing
p66Shc or increasing Sirt1 activity), but not the reduction of circulat-
ing ROS levels once they have been already produced, plays a key
role in reducing age-related diseases.
Studies on GDF11 reported surprising results about the efficacy
of this factor in aging and few but significant evidences have shown
that GDF11 could represent a valuable target for CV and CBV
diseases.
The herein described target proteins offer insights to better char-
acterize underlying mechanisms of CV and CBV diseases in aging;
however, additional work needs to be done to elucidate their pos-
sible interactions and to finalize the characterization of their
molecular pathways.
Future perspectives
To date, much is known to the research community about CV and
CBV aging as well as the molecules and molecular mechanisms in-
volved in this process. However, the complex interplay between
these mediators is far from being elucidated. A better understanding
of the molecular and cellular mechanisms underlying vascular aging,
as well as their potential interactions, will provide a list of candidate
molecules which could be considered as targets for specific inter-
ventions aimed at delaying vascular aging. Oxidative stress together
with inflammation is among those mechanisms which could be con-
sidered as targets for future treatment or for the development of
novel and reliable biomarkers to improve the understanding of
risk factor stratification. Finally, the individual molecules discussed
in details in this review could set the basis for additional studies
aimed at finding possible targets for therapeutical intervention to
delay the onset vascular aging.
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